[HTML][HTML] Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN …
Background Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with
a high risk of metastasis. In 2017, avelumab (anti–programmed death-ligand 1 (PD-L1)) …
a high risk of metastasis. In 2017, avelumab (anti–programmed death-ligand 1 (PD-L1)) …
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel …
SP D'Angelo, S Bhatia, AS Brohl… - Journal for …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with
a high risk of metastasis. In 2017, avelumab (anti-programmed death-ligand 1 (PD-L1)) …
a high risk of metastasis. In 2017, avelumab (anti-programmed death-ligand 1 (PD-L1)) …
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel …
SP D'Angelo, S Bhatia, AS Brohl, O Hamid… - … for Immunotherapy of …, 2020 - amigos.org.au
In 2017, avelumab (anti-programmed death-ligand 1 (PD-L1)) became the first approved
treatment for patients with metastatic MCC (mMCC), based on the occurrence of durable …
treatment for patients with metastatic MCC (mMCC), based on the occurrence of durable …
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: Long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel …
SP D'Angelo, S Bhatia, AS Brohl… - Journal for …, 2020 - research.uni-luebeck.de
Background Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with
a high risk of metastasis. In 2017, avelumab (anti-programmed death-ligand 1 (PD-L1)) …
a high risk of metastasis. In 2017, avelumab (anti-programmed death-ligand 1 (PD-L1)) …
[PDF][PDF] Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN …
SP D'Angelo, S Bhatia, AS Brohl, O Hamid, JM Mehnert… - scholar.archive.org
AbstrACt background Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer
associated with a high risk of metastasis. In 2017, avelumab (anti–programmed deathligand …
associated with a high risk of metastasis. In 2017, avelumab (anti–programmed deathligand …
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel …
SP D'Angelo, S Bhatia, AS Brohl… - Journal for …, 2020 - search.proquest.com
Background Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with
a high risk of metastasis. In 2017, avelumab (anti–programmed death-ligand 1 (PD-L1)) …
a high risk of metastasis. In 2017, avelumab (anti–programmed death-ligand 1 (PD-L1)) …
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: Long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel …
SP D'Angelo, S Bhatia, AS Brohl… - Journal for …, 2020 - researchwithrutgers.com
Background Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with
a high risk of metastasis. In 2017, avelumab (anti-programmed death-ligand 1 (PD-L1)) …
a high risk of metastasis. In 2017, avelumab (anti-programmed death-ligand 1 (PD-L1)) …
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel …
SP D'Angelo, S Bhatia, AS Brohl, O Hamid… - … for Immunotherapy of …, 2020 - europepmc.org
Background Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with
a high risk of metastasis. In 2017, avelumab (anti–programmed death-ligand 1 (PD-L1)) …
a high risk of metastasis. In 2017, avelumab (anti–programmed death-ligand 1 (PD-L1)) …
[PDF][PDF] Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN …
SP D'Angelo, S Bhatia, AS Brohl, O Hamid, JM Mehnert… - merkelcell.org
AbstrACt background Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer
associated with a high risk of metastasis. In 2017, avelumab (anti–programmed deathligand …
associated with a high risk of metastasis. In 2017, avelumab (anti–programmed deathligand …
[HTML][HTML] Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN …
SP D'Angelo, S Bhatia, AS Brohl, O Hamid… - … for ImmunoTherapy of …, 2020 - jitc.bmj.com
Background Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with
a high risk of metastasis. In 2017, avelumab (anti–programmed death-ligand 1 (PD-L1)) …
a high risk of metastasis. In 2017, avelumab (anti–programmed death-ligand 1 (PD-L1)) …